Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erythropoietin chitosan gel is an investigational topical biologic formulation developed by researchers at Ain Shams University. It consists of erythropoietin (EPO) incorporated into a thermosensitive hydrogel scaffold composed of 5% chitosan and 20% β-glycerophosphate disodium salt. The formulation is designed for topical application in periodontal surgery, specifically as an adjunct to split-thickness apically positioned flap procedures. Erythropoietin acts as a cytoprotective and pro-angiogenic agent that promotes tissue repair, stimulates cell proliferation, and exerts anti-inflammatory effects, thereby enhancing wound healing and increasing the width of attached gingiva in patients with gingival recession.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on erythropoietin chitosan gel.